President Donald Trump demands drugmakers match global prices or face federal action, citing abusive pricing and pledging to ...

According to the Washington Post, 13 states currently cover the drugs for Medicaid patients, while Medicare prohibits ...

JPMorgan U.S. Momentum Factor ETF has diversified momentum exposure, competitive returns, and low expenses. Read here for an ...

Eli Lilly remains a top stock to buy and hold. Vertex Pharmaceuticals is moving quickly to expand its markets beyond cystic ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...

HYDERABAD — Dr Reddy’s Laboratories is gearing up to enter the booming global obesity drug market with a more affordable ...

State Medicaid programs already are allowed to offer GLP-1 drugs for weight loss, but only 13 state programs currently do so. Meanwhile, Medicare currently covers GLP-1 drugs for people with a ...

The drugs reportedly under consideration for coverage include Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and ...

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under ...

Is Novo Nordisk stock a buy? An analysis of $NVO, its weight loss drugs Ozempic and Wegovy, and market share competition with ...

He said if they didn't, the US would deploy 'every tool in our arsenal' to protect families from 'continued abusive drug ...

Pfizer CEO Albert Bourla is expected to attend a $25 million fundraiser at US President Donald Trump’s golf club in ...